Category: Pharmaceuticals
Pharmaceuticals market research reports by Bonafide Research & Marketing Pvt. Ltd.
-
Mexico Biosimilars Market Overview, 2030
An increase in awareness and acceptance of biosimilars among healthcare professionals in Mexico is another significant trend that is fueling market growth. Previously, physicians and healthcare professionals were somewhat hesitant to transition from originator biologics to biosimilars because they w ... Read More
-
India Biosimilars Market Overview, 2030
Biosimilars, a category of biological medical products, closely emulate original reference biologic drugs, ensuring comparable safety, purity, and potency without clinically significant differences. Unlike generic drugs, which are exact copies of small-molecule chemical drugs, biosimilars cannot rep ... Read More
-
Brazil Biosimilars Market Overview, 2030
The Brazil Biosimilars market will grow with The increased incidence of chronic illnesses, rising healthcare expenses, and the demand for affordable biologic medicine substitutes. Brazil is the ninth-largest economy in the world, and it boasts one of the biggest and most complicated healthcare syste ... Read More
-
Europe Biosimilars Market Outlook, 2030
Europe has played a pioneering role in the development, approval, and adoption of biosimilars, being the first region globally to establish a regulatory pathway for these drugs with the European Medicines Agency (EMA) issuing the first biosimilar approval in 2006. Since then, the European market has ... Read More
-
Australia Biosimilars Market Overview, 2030
The regulatory body for therapeutic goods in Australia is the Therapeutic Goods Administration (TGA). TGA is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating therapeutic goods including medicines, medical devices, blood and blood products, in ... Read More
-
Global Biosimilars Market Overview, 2025-30
Biosimilars are safe, effective, and highly similar versions of approved and authorized biologics. A biological drug is a large and complex protein produced from living cells through complex manufacturing processes. As patents for many blockbuster biologics expire, biosimilars present an opportunity ... Read More
-
Germany Biosimilars Market Overview, 2030
Biosimilars are biological drugs that are extremely similar to a reference drug, a biological drug that has already received approval. They are designed to be equally safe and effective as the reference drug. The European Medicines Agency (EMA), which establishes standards for their research and app ... Read More
-
Global Biosimilars Market Outlook, 2030
BiosimilarsThe biosimilars industry has emerged as a transformative force in the global healthcare landscape, representing a vital frontier in biopharmaceutical innovation and affordability. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic, ... Read More
-
Canada Biosimilars Market Overview, 2030
Potential savings from biosimilars are a subject of keen interest internationally, with a particular relevance for Canadians. Given the high use and cost of biologics in Canada, the increased use of biosimilars offers a significant opportunity for cost savings for Canadian payers. Unlike small molec ... Read More
-
China Biosimilars Market Overview, 2030
Biosimilars have played a significant role in alleviating healthcare burdens and enhancing patient access to high-quality biologic-based pharmaceutical therapies. The World Health Organization (WHO), as well as various national governments and regulatory agencies, have established corresponding regu ... Read More
-
South Africa Biosimilars Market Overview, 2030
Traditionally, the pharmaceutical market has been known for its production of chemical synthetic medicines generally referred to as originators and generic medicines. However, in the last decade, there has been an increasing interest in more technologically advanced and effective medicines such as b ... Read More
-
Asia-Pacific Biosimilars Market Outlook, 2030
The Asia Pacific region, comprising countries such as China, India, Japan, South Korea, Australia, and Southeast Asian nations, plays an increasingly pivotal role in the global biosimilars market due to its growing manufacturing capabilities, improving regulatory frameworks, and expanding patient ba ... Read More
-
United Kingdom Biosimilars Market Overview, 2030
Biosimilars are a type of biological medicine and are widely used in the UK for many conditions. Biological medicines are complex medicines made or derived from a biological source. The biosimilar contains a version of an active substance of an already approved biological medicinal product, known as ... Read More
-
Japan Biosimilars Market Overview, 2030
Biosimilars are pharmaceutical medications that are highly similar to an existing biological reference product, known as the originator or reference biologic. Biosimilars are designed to be comparable in quality, safety, and efficacy to the reference product while being less expensive. They are an a ... Read More
-
Columbia Biosimilars Market Overview, 2030
Colombia is emerging as a key player, thanks to its agile regulatory framework, an active authority such as INVIMA, and policies that promote access to biotechnological medicines. In recent years, Colombia has made significant regulatory advances. INVIMA has implemented measures to streamline biosim ... Read More
-
Middle East & Africa Biosimilars Market Outlook, 2030
MEA, particularly in the treatment of diseases such as cancer, diabetes, autoimmune disorders, and inflammatory conditions. The high cost of original biologic drugs, combined with budget constraints in many MEA countries, has fueled interest in biosimilars as cost-effective alternatives. Governments ... Read More
-
North America Biosimilars Market Outlook, 2030
Biosimilars are biological products that are highly similar to already approved reference biologics, offer significant promise in terms of enhancing patient access to critical therapies for chronic and life-threatening conditions such as cancer, rheumatoid arthritis, and diabetes. The United States ... Read More
-
United States Biosimilars Market Overview, 2030
Biologic therapies play a critical role in modern medical practice but also present challenges for payers, patients, and other stakeholders because of their high cost. Biosimilars can mitigate the cost pressures of reference biologic therapy because they are typically priced at least 25% lower, prov ... Read More
-
Spain Biosimilars Market Overview, 2030
Spain has been one of the leaders in the use of biosimilars, with a robust regulatory framework and policies in place to promote the use of these drugs. Biosimilars are an important part of the pharmaceutical industry in Spain, offering a more affordable and accessible alternative to biological drug ... Read More
-
UAE Biosimilars Market Overview, 2030
The UAE Biosimilars market will grow as biosimilars are less expensive than their reference products, and patients can afford to use biosimilars as a therapy alternative. The United Arab Emirates (UAE) offers a sophisticated healthcare system with first-rate facilities and cutting-edge medical techn ... Read More
-
Saudi Arabia Biosimilars Market Overview, 2030
In Saudi Arabia, as the biosimilars are about to capture the pharma market, hence it is essential to determine the current awareness in terms of knowledge and awareness about biosimilars among physicians in Saudi Arabia. To date, there is a lack of published data about physicians’ knowledge and awar ... Read More
-
Italy Biosimilars Market Overview, 2030
Italy's biosimilars industry is experiencing significant growth, driven by a combination of regulatory support, cost-saving imperatives, and increasing demand for affordable biologic therapies. The Italian Medicines Agency (AIFA) plays a pivotal role in this expansion by implementing policies that e ... Read More
-
France Biosimilars Market Overview, 2030
In France, biosimilars play an important role in reducing health costs while maintaining quality of care. This economic concern is even more important given the current context (economic crisis, budgetary pressure, aging population, therapeutic innovation, etc.), that biologics and their biosimilars ... Read More
-
South Korea Biosimilars Market Overview, 2030
Driven by the country’s advanced clinical research infrastructure and government support, South Korea has, over the last decade, emerged as a global leader in the biopharmaceutical industry. Key companies like Celltrion, a biopharmaceutical company with an extensive pipeline portfolio which includes ... Read More
-
Argentina Biosimilars Market Overview, 2030
Argentina's biosimilars industry is experiencing significant growth, driven by a combination of regulatory advancements, strategic public-private partnerships, and a focus on cost-effective healthcare solutions. In the dynamic landscape of South America's pharmaceutical industry, Argentina stands ou ... Read More
Research Assistance
